Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen to Acquire Molecular Dx Test Maker Artus for $39.2M

NEW YORK, May 31 (GenomeWeb News) - Qiagen will acquire Artus of Germany, a maker of PCR-based diagnostic tests, for approximately $39.2 million in cash, the company said today.

 

Artus, located in Hamburg, focuses on diagnostic tests based on PCR and RT-PCR for infectious disease detection, pharmacogenomics, and veterinary diagnostics. The company, founded in 1998 as a spin-off from the Bernhard-Nocht-Institute for Tropical Medicine in Hamburg, sells more than 60 assays to detect viral and bacterial pathogens and has distribution agreements with Abbott Laboratories and MWG Biotech.

 

Qiagen said in a statement that "this acquisition is a perfect fit in its strategy to increase Qiagen's value as a partner to the molecular diagnostics industry." The company expects the acquisition will add about $15 million in net sales and $1.5 million to $2 million in net income to its 2006 earnings.

 

Qiagen reported $380.6 million in revenues for its 2004 fiscal year.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.